Cancer R&D is thriving. Here are the areas to watch in 2026.

ADCs, radioligand therapies and multispecifics are leading the way in cancer innovation.

By Kelly Bilodeau • Jan. 21, 2026

Texas, N. Carolina, Ohio, Pennsylvania — where pharma manufacturing investments have surged

Pledged projects have landed in a handful of hotspots while giving rise to potential new hubs across the U.S.

By Alexandra Pecci • Jan. 20, 2026

Explore the Trendline➔

Oncology R&D

Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

By PharmaVoice staff

The clinical candidates pharma execs are tracking

Industry leaders at JPM this week revealed which up-and-coming assets they’re watching from other companies in oncology and neuroscience.

By Meagan Parrish • Jan. 16, 2026

3 positive trends for Massachusetts’ biopharma sector

Despite a rocky landscape for the biotech industry nationally, Massachusetts has shown innovation growth and stronger funding than expected, which could bode well for the future.

By Michael Gibney • Jan. 13, 2026

A biotech’s snakebite pill is drawing the US military’s interest

Backed by the Department of Defense, Ophirex is developing the first oral snakebite treatment, making on-the-ground treatment possible for the first time.

By Alexandra Pecci • Jan. 13, 2026

What Sanofi’s multiple sclerosis troubles could mean for the space

The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug class. 

By Kelly Bilodeau • Jan. 12, 2026

PharmaVoice’s Crystal Ball: What’s next for AI and drug R&D

Industry execs foresee drug innovation and AI breakthroughs in 2026.

By Meagan Parrish • Jan. 9, 2026

Billionaire Sean Parker has already shaken up cancer R&D. Can his nonprofit fix the funding gap?

The entrepreneur’s cancer institute is striving to be the financial glue for an embattled research community while going beyond therapies and creating cures.

By Michael Gibney • Jan. 8, 2026

5 FDA drug approvals to watch in 2026

Potential blockbusters and root-cause treatments from Eli Lilly, Merck, Takeda and others could get a regulatory nod this year.

By Alexandra Pecci • Jan. 7, 2026

C-suite priorities give a sneak peek into AI’s pharma future

While some are still leery of the technology, leaders see AI as a way to boost efficiency and cut costs.

By Kelly Bilodeau • Jan. 7, 2026

3 of China’s most innovative pharma companies

The top Chinese drugmakers succeeding in both innovation and business savvy.

By Kelly Bilodeau • Jan. 5, 2026

Beyond Botox: AbbVie’s push for broader gains in neurotoxin R&D

The large pharma is advancing two next-generation neurotoxins in both the therapeutic and aesthetic spaces.

By Alexandra Pecci • Dec. 23, 2025

Biopharma CEO optimism is wavering in the US

The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.

By Kelly Bilodeau • Dec. 22, 2025

Biogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth

Guy Hadari discusses how his role has changed with the introduction of new technologies, and what that means for Biogen’s future.

By Michael Gibney • Dec. 19, 2025

The leading GLP-1 contenders in pharma’s race for an obesity pill

Recent mid-stage readouts reveal how the market for an oral weight loss drug could take shape. 

By Alivia Kaylor • Dec. 18, 2025

3 key takeaways from the FDA’s new animal testing guidance

The agency’s moves to end animal testing are “not a fluke.” Here’s what drugmakers need to know about where it goes from here.

By Alexandra Pecci • Dec. 17, 2025

How the FDA could soon upend vaccine trials

Vaccinemakers should be prepared to pivot to meet new requirements by ensuring strong communication.

By Kelly Bilodeau • Dec. 17, 2025

Amylyx pins its next hopes on a niche drug in the obesity space

A lot is riding on Amylyx’s late-stage candidate for post-bariatric hypoglycemia.

By Meagan Parrish • Dec. 12, 2025

Pharma’s top deals in 2025

The year’s three largest acquisitions signal where pharma is willing to pay big for promising candidates.

By Michael Gibney • Dec. 11, 2025

Another genetic testing company? Why a different approach could boost drug predictions and R&D.

Genetic tests could soon play a larger role in clinical trials and predicting adverse events.

By Alexandra Pecci • Dec. 10, 2025

How Lilly uses Big Pharma heft to lift up-and-coming biotechs

With great power comes great responsibility, and Eli Lilly is employing financial success and technical know-how to give smaller biotechs a leg up.

By Michael Gibney • Dec. 9, 2025

BeOne brought Brukinsa to the blood cancer mountaintop. Can it hit those heights again?

The company’s chief medical officer discusses its trajectory with the blockbuster Brukinsa and its strong hematology pipeline.

By Michael Gibney • Dec. 4, 2025

Hemophilia gene therapies are struggling on the market, even as innovation soars

The business case for hemophilia gene therapy still isn’t adding up due to persistent market barriers.

By Kelly Bilodeau • Dec. 3, 2025

4 major changes at the FDA this year

The most impactful regulatory shifts for pharma in 2025 and how the industry can take advantage of new policies. 

By Alexandra Pecci • Dec. 3, 2025

Novo, J&J Alzheimer’s clinical flops teach bruised field valuable lessons

November was a tough month for highly anticipated Alzheimer’s readouts with a GLP-1 and tau-targeting drug coming up short in late-stage trials.

By Michael Gibney • Dec. 2, 2025